Evidence map›Paper›PMID 40751251›Full record

ArticleBiotechnology for biofuels and bioproducts2025

Metabolic engineering of Saccharomyces cerevisiae for co-production of ethanol and 3-methyl-1-butanol from sugarcane molasses.

Sasha Yogiswara, Jonas Rombout, Giovanni Micharikopoulos, Sam De Craemer, Beatriz Herrera-Malaver, Lotte van Landschoot, Sofie Mannaerts, Marcelo do Amaral, Karin Voordeckers, Stijn Spaepen and 4 more

Abstract read
In one paragraph

Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Effect of jabuticaba (Plinia jaboticaba) extract on mead fermentation by Saccharomyces cerevisiae and volatile composition.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sasha YogiswaraVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Jonas RomboutVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Giovanni MicharikopoulosVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Sam De CraemerLaboratory of Applied Mass Spectrometry, Department Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Beatriz Herrera-MalaverVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Lotte van LandschootVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Sofie MannaertsVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Marcelo do AmaralLeaf By Lesaffre, 59703, Marcq-en-Barœul Cedex, France.
Karin VoordeckersVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Stijn SpaepenVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Jan SteenselsVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Quinten DeparisVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium.
Bart GhesquièreLaboratory of Applied Mass Spectrometry, Department Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Kevin J VerstrepenVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3001, Leuven, Belgium. Kevin.Verstrepen@kuleuven.be.

Funding

Bijzondere Onderzoeksfondsen IBOF/21/092Fonds Wetenschappelijk Onderzoek 1S22422NFonds Wetenschappelijk Onderzoek I002722NFonds Wetenschappelijk Onderzoek S001421N
6 · The paper itself

Abstract

3-Methyl-1-butanol (3MB) is a promising renewable solvent, drop-in fuel, and precursor for various industrial products, including flavors, fragrances, and surfactants. Due to the myriad of intertwined biosynthetic pathways that share metabolic precursors, conventional metabolic engineering strategies to overproduce 3MB in yeast have typically resulted in yields that are far too low for economic viability. However, because 3MB is naturally produced by yeast, 100 million liter of 3MB are already produced annually as a byproduct of bioethanol fermentations. Despite its significant commercial value, this 3MB fraction is currently discarded due to its low relative concentration within the fusel alcohol mixture. Here, we present a novel strategy to produce 3MB along with the conventional bioethanol fermentation, leveraging the existing bioethanol industry by valorizing the discarded fusel alcohol byproduct stream. We first identified a robust industrially relevant chassis strain and explored different strategies to alleviate the valine and leucine feedback inhibition within the 3MB pathway, showing that mutating the leucine-inhibition site of Leu4p increased 3MB yield by 2.9-fold. Finally, we tested in silico-predicted gene deletion targets to reduce the byproduct acetate. Our final engineered strain achieved a 4.4-fold increase in 3MB yield compared to the wild type (1.5 mg/g sugars), average productivity of 5 mg/Lh, and a 3MB proportion increase from 42 to 71% within the fusel alcohol mix, while ethanol production remained comparable to the Ethanol Red® industrial reference. Our study thus opens a new route for co-producing 3MB and ethanol from sugarcane molasses in Saccharomyces cerevisiae, laying the groundwork toward an economically viable and sustainable approach for 3MB production alongside existing bioethanol production.

Indexed as

3-Methyl-1-butanolBioethanol productionBranched-chain amino acidFusel alcoholsIsoamyl alcoholSustainable chemistryYeast metabolic engineering

Identifiers

PMID40751251
PMCPMC12317478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.